Institutul Oncologic Prof. Dr. I. Chiricuta Cluj-Napoca

Clement What the numbers say about this buyer

• The median procedure drew 9 bids (8,980 procedures with a bid count); 3% ended with a single bidder. Country: median 5.3 bids.n = 8,980
• 90% of this buyer's awards went to companies that had already won here before (11,482 awards since 2019, spread over 635 companies). That is well above the national norm (76%) — newcomers have a harder time here than elsewhere.n = 11,482 awards since 2019
• The award came in at a median 60% of the estimated value (9 awards with both estimate and value) — pricing at the estimate is usually too high here. Country: 83%.n = 9
• 83% of the bids received came from small and medium-sized enterprises (8,845 procedures with a bid mix). Country: 68%.n = 8,845
• 4% of awards went to companies from abroad (11,482 awards with a known winner country). National average: 1%.n = 11,482
• Across 16 procedures with structured selection criteria, this buyer most often required: Trade register enrolment (16 of 16), Special authorisation or membership required (6 of 16), Quality control by institutes (4 of 16), Staff qualifications (3 of 16).n = 16
• 1% of the bids received came from other countries (8,845 procedures with a bid mix) — all bidders, not just the winners. Country: 2%.n = 8,845

From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 31/10/2026.